United States securities and exchange commission logo





                            April 6, 2023

       Shao-Lee Lin, MD
       Chief Executive Officer
       ACELYRIN, Inc.
       4149 Liberty Canyon Road
       Agoura Hills, CA 91301

                                                        Re: ACELYRIN, Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted on March
24, 2023
                                                            CIK 0001962918

       Dear Shao-Lee Lin:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No.1 to Draft Registration Statement submitted March 24, 2023

       Prospectus Summary
       Summary Overview of Izokibep, page 3

   1.                                                   We note your response
to our prior comment one and reissue our comment. Throughout
                                                        your filing you
continue to make statements and predictions regarding the efficacy of your
                                                        product candidates. As
stated, efficacy conclusions are within the sole authority of the
                                                        FDA and are assessed
throughout the entire development process. Please remove all
                                                        statements related to
the safety and efficacy of your product candidates here and
                                                        throughout your
registration statement. For example:
                                                            "izokibep has
demonstrated clinically meaningful responses"
                                                            "we believe the
enthesitis resolution response of izokebep demonstrated in PsA could
 Shao-Lee Lin, MD
FirstName   LastNameShao-Lee Lin, MD
ACELYRIN,      Inc.
Comapany
April       NameACELYRIN, Inc.
       6, 2023
April 26, 2023 Page 2
Page
FirstName LastName
              also be indicative of similar clinically meaningful responses . .
.."
                "In the trial, both the 40mg and 80mg doses of izokibep
demonstrated significant
              improvements compared to placebo."
                "The PsAID results for the overall population in this trial
revealed statistically
              significant and dose-dependent improvements in all
quality-of-life sub-domains of
              the PsAID instrument . . ."

         Please note that you should present the objective data from your
trials without drawing
         conclusions as to whether they demonstrated efficacy. Additionally,
note this is not an
         inclusive list of the efficacy claims you have included in your
filing. Please review your
         filing thoroughly and remove all claims related to the efficacy your
your product
         candidates.
2.       We note your response to comment three and note you have revised your
disclosure to
         indicate that orphan drug status does not guarantee that a regulatory
authority will accept
         fewer trials or accelerate regulatory review. However, it is not until
page 167 that you
         clarify that orphan drug status does not provide any advantage with
respect to shortening
         the duration of the regulatory review and approval process. The
revised disclosure on
         pages 3, 31, 124 and 127 continues to imply that orphan drug status
may result in a shorter
         process. Please revise to clarify that it conveys no advantage in or
shorten the duration of
         the regulatory review and approval process.
3.       We note your response to comments 4 and 20. However, your revised
disclosure indicates
         that you are relying on a demonstrated response from an ongoing trial
to determine that
         the candidate may also demonstrate clinically meaningful responses for
patients with
         AxSpA. Please remove the references to "the enthesitis resolution
response izokibep
         demonstrated in PsA" and clarify that the FDA has not consented to
your plans to conduct
         only one Phase 3 clinical trial for Izokibep for AxSPA. You may
indicate that you are
         relying on data related to enthesitis from your PsA trials in seeking
FDA approval to
         proceed directly to a Phase 2b/3 trial without indicating your
conclusions with respect to
         the efficacy of that trial. Additionally, revise your pipeline table
to clarify that you have
         not completed a Phase 2 trial. Until the FDA clarifies that a Phase 2
trial is not required, it
         is not appropriate to indicate that you have completed Phase 2 in your
pipeline table on
         pages 2 and 125.
Unaudited Pro Forma Condensed Combined Financial Information
3. Pro Forma Adjustments, page 100

4.       For the amount allocated to in-process research and development,
please disclose a
         breakout of the amount due to the lonigutamab and XLRN-517 product
candidates,
         separately.
Affibody Agreement, page 106

5.       We note your response to comment ten. Please further expand your
disclosure to clarify
 Shao-Lee Lin, MD
ACELYRIN, Inc.
April 6, 2023
Page 3
      what "certain marketing applications" qualify for priority review
vouchers. For example,
      clarify whether all candidates with orphan drug status qualify for
priority review
      vouchers. If not, describe the factors the FDA considers in determining
whether to to
      award a priority review voucher.
Business, page 123

6.    Throughout your business section you compare your product candidates to
efficacy
      information related to potential competitors. For example, on page 139,
you state that you
      have used published data for all approved therapies for treatment of PsA.
While you may
      indicate that ACR50 response rates at 16 weeks ranging from 35-45% was
your trial
      endpoint if that was the case, you may not present the comparison of your
candidate to
      other products or third party product candidates unless you have
conducted head to head
      trials. Please revise your registration statement accordingly.
Our ongoing Phase 2b/3 Trial of Izokibep in HS, page 136

7.    Please explain why you have provided the placebo response rates that have
been reported
      by by other agents in their historical clinical trials and clarify
whether and how the FDA
      has agreed to allow you to use these results in your trial.
8.    Please delete the statement that "achievement of HiSCR100 response at
Week 12 does not
      appear, to our knowledge, to have been previously for any other product."
Ongoing Phase 2b/3 Trial in Uveitis, page 147

9.    Please clarify that the ongoing Phase 2b/3 trial is your first clinical
trial for uveitis.
      Similarly, clarify this information by footnote or otherwise in your
pipeline table on pages
      2 and 125.
       You may contact Ibolya Ignat at 202-551-3636 or Vanessa Robertson at
202-551-3675 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Cindy Polynice at 202-551-8707 or Suzanne Hayes at 202-551-3675 with
any other
questions.



                                                            Sincerely,
FirstName LastNameShao-Lee Lin, MD
                                                            Division of
Corporation Finance
Comapany NameACELYRIN, Inc.
                                                            Office of Life
Sciences
April 6, 2023 Page 3
cc:       Anitha Anne., Esq.
FirstName LastName